[Webinar] China Modified MDR (Order 739) Has Arrived— Opportunity Knocks: Quality Management System, Design Control, Post-Market Surveillance


Register Now

Date: Thursday, September 2, 2021, 7:00-8:00 AM Pacific Time (US and Canada)


With the implementation of Order 739 in July 2021, China National Medical Product Administration (NMPA) continues to strengthen the product lifecycle supervision and impose heavier penalties on illegal violations. This live webinar aims to help the audience understand fundamentals of medical device QMS/GMP in China, align with the most recent NMPA regulatory updates, and learn more details about the post-market surveillance requirements in China. You should be able to answer the following questions as a foreign medical device manufacturer, NMPA certificate holder, legal agent, and distributor in China:



Guobao Wei, PhD

Sr. Quality Manager, Siemens Healthineers

Dr. Wei has extensive experience in medical device product development, manufacturing process innovation. and organizational quality excellence. He holds more than 40 patents in biological technologies and is an ASQ certified Quality Manager (CMQ/OE), Quality Engineer (CQE) and Quality Auditor (CQA).

Zhe Ji

QA Manager, Inspirative Medical

Zhe has over 15 years of experience in medical device quality assurance as a team leader for product lifecycle supervision in China. She has extensive hands-on experience in handling post-market recalls, adverse events, and inspections, submitting periodic reports, providing trainings, and maintaining communication with China NMPA.

Registration Link